At 15.3% CAGR, the Asia Pacific Biopharmaceuticals Market is projected to be worth US$ 94.13 billion by 2028, says Business Market Insights

According to Business Market Insights research, the Asia Pacific biopharmaceuticals market was valued at US$ 39.96 billion in 2022 and is expected to reach US$ 94.13 billion by 2028, registering a CAGR of 15.3% from 2022 to 2028. Potential to treat rare diseases and accelerated clinical trials are the critical factors attributed to the Asia Pacific biopharmaceuticals market expansion.               

Complex biology associated with rare diseases presents challenges for scientists to design and implement new drug development programs. However, despite these challenges, biopharmaceuticals researchers in the Americas have developed new technologies for treating rare diseases and developing groundbreaking therapies. These advancements include the development of groundbreaking therapies such as hemophilia A, spinal muscular atrophy, juvenile idiopathic arthritis, inherited retinal diseases, and transthyretin amyloid cardiomyopathy by biopharmaceuticals researchers. Further, biopharmaceuticals company Ultragenyx Pharmaceutical Inc. is engaged in the safety testing and dosage determination of molecules developed to treat Glycogen Storage Disease (GSD) type 3, a serious rare and ultra-genetic disease. The company initiated the clinical studies of UX053 in December 2021 to launch it as the first potential medicine for treating patients living with GSD3. The UX053 mRNA can deliver large genes to targeted cells for achieving a high uniformity of protein expression. The company plans to individualize mRNA therapies based on the needs of each patient through the adjustment of dose levels and frequency. Such clinical developments, launches, and approvals are accelerating the Asia Pacific biopharmaceuticals market expansion.  

On the contrary, high cost of manufacturing infrastructure hurdles the growth of Asia Pacific biopharmaceuticals market.

Based on product type, the Asia Pacific biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. The monoclonal antibodies segment held 46.1% share of Asia Pacific biopharmaceuticals market in 2022, amassing US$ 18.42 billion. It is projected to garner US$ 45.08 billion by 2028 to expand at 16.1% CAGR during 2022–2028. The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, ebola vaccine, hepatitis-b vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth Factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.

Based on application, the Asia Pacific biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. The oncology segment held 33.1% share of Asia Pacific biopharmaceuticals market in 2022, amassing US$ 13.22 billion. It is projected to garner US$ 30.51 billion by 2028 to expand at 15.0% CAGR during 2022–2028.  

Based on country, the Asia Pacific biopharmaceuticals market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 29.3% share of Asia Pacific biopharmaceuticals market in 2022. It was assessed at US$ 11.69 billion in 2022 and is likely to hit US$ 27.25 billion by 2028, exhibiting a CAGR of 15.2% during the forecast period.  

Key players profiles in the Asia Pacific biopharmaceuticals market report AbbVie Inc; AGC Biologics AS; Amgen Inc; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Co; Eli Lilly and Co; Johnson & Johnson; Lonza Group AG; Thermo Fisher Scientific Inc; and WuXi Biologics Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com